Ocugen Inc

NASDAQ:OCGN  
2.50
-0.04 (-1.58%)
Products

Ocugen Announces Publication Of Positive Results Of Covid-19 Vaccine Trial For Children 2-18 In The Lancet Infectious Diseases

Published: 06/21/2022 13:52 GMT
Ocugen Inc (OCGN) - Ocugen Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2-18 in the Lancet Infectious Diseases.
Ocugen Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2-18 in the Lancet Infectious Diseases.
Ocugen Inc- Bharat Biotech's Phase 2/3 Study of Covaxin™ (bbv152) in 526 Children Showed Safety, Efficacy, and Superior Response to That Shown in Adults.